000			01799 a2200505 4500
005			20250517054154.0
264		0	_c20161014
008			201610s 0 0 eng d
022			_a1468-3083
024	7		_a10.1111/jdv.13305 _2doi
040			_aNLM _beng _cNLM
100	1		_aLayton, A M
245	0	0	_aBrimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. _h[electronic resource]
260			_bJournal of the European Academy of Dermatology and Venereology : JEADV _cDec 2015
300			_a2405-10 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdrenergic alpha-2 Receptor Agonists _xadverse effects
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aBrimonidine Tartrate _xadverse effects
650	0	4	_aErythema _xdrug therapy
650	0	4	_aFacial Dermatoses _xdrug therapy
650	0	4	_aFemale
650	0	4	_aGels
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPatient Satisfaction
650	0	4	_aRosacea _xcomplications
650	0	4	_aSeverity of Illness Index
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aSchaller, M
700	1		_aHomey, B
700	1		_aHofmann, M A
700	1		_aBewley, A P
700	1		_aLehmann, P
700	1		_aNohlgård, C
700	1		_aSarwer, D B
700	1		_aKerrouche, N
700	1		_aMa, Y M
773	0		_tJournal of the European Academy of Dermatology and Venereology : JEADV _gvol. 29 _gno. 12 _gp. 2405-10
856	4	0	_uhttps://doi.org/10.1111/jdv.13305 _zAvailable from publisher's website
999			_c25305214 _d25305214